Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2022 / N 1

Диабетическая полиневропатия: от патогенеза к диагностике и лечению
К.В. Антонова, О.В. Лагода

References

1. International Diabetes Federation. IDF diabetes atlas, 2021. 10th ed. Brussels, Belgium: IDF; 2021. 141 p. Available from: https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf Accessed 2022 Apr 21.
2. Ministry of Health of the Russian Federation; Russian Association of Endocrinologists; National Medical Research Center of Endocrinology. Clinical recommendations. "Standards of specialized diabetes care". Dedov II, Shestakova MV, Mayorov AYu, editors. 10th issue. Moscow, 2021. 223 p. (In Russian).
3. American Diabetes Association. 11. Microvascular complications and foot care: Standards of medical care in diabetes – 2020. Diabetes Care 2020 Jan;43(Suppl 1):S135-51.
4. American Diabetes Association. 11. Microvascular complications and foot care: Standards of medical care in diabetes – 2019. Diabetes Care 2019 Jan;42(Suppl 1):S124-38.
5. Ziegler D, Papanas N, Vinik AI, Shaw JE. Epidemiology of polyneuropathy in diabetes and prediabetes. Handbook of Clinical Neurology 2014;126:3-22.
6. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001 Nov;44(11):1973-88.
7. Sloan G, Shillo P, Selvarajah D, Wu J, Wilkinson ID, Tracey I, Anand P, Tesfaye S. A new look at painful diabetic neuropathy. Diabetes Research and Clinical Practice 2018;144:177-91.
8. Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, Bril V, Russell JW, Viswanathan V. Diabetic neuropathy. Nature Reviews. Disease Primers 2019 Jun;5(1):41.
9. Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Rayaz Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010 Oct;33(10):2285-93.
10. Bönhof GJ, Herder C, Strom A, Papanas N, Roden M, Ziegler D. Emerging biomarkers, tools, and treatments for diabetic polyneuropathy. Endocrinology Review 2019 Feb;40(1):153-92.
11. Garcia Soriano F, Virág L, Jagtap P, Szabó E, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murthy KG, Salzman AL, Southan GJ, Szabó C. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nature Medicine 2001 Jan;7(1):108-13.
12. Pacher P, Szabó C. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxidants & Redox Signaling 2005 Nov-Dec;7(11-12):1568-80.
13. Federico A, Cardaioli E, Da Pozzo P, Formichi P, Gallus GN, Radi E. Mitochondria, oxidative stress and neurodegeneration. Journal of the Neurological Sciences 2012 Nov;322(1-2):254-62.
14. Németh N, Putz Z, Istenes I, Körei AE, Vági OE, Kempler M, Gandhi R, Jermendy G, Tesfaye S, Tabák ÁG, Kempler P. Is there a connection between postprandial hyperglycemia and IGT related sensory nerve dysfunction? Nutrition, Metabolism & Cardiovascular Diseases 2017 Jul;27(7):609-14.
15. Brannick B, Wynn A, Dagogo-Jack S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Experimental Biology and Medicine (Maywood, N.J.) 2016 Jun;241(12):1323-31.
16. Ziegler D, Tesfaye S, Spallone V, Gurieva I, Al Kaabi J, Mankovsky B, Martinka E, Radulian G, Nguyen KT, Stirban AO, Tankova T, Varkonyi T, Freeman R, Kempler P, Boulton AJ. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations. Diabetes Research and Clinical Practice 2021 Sep 20;109063. doi: 10.1016/j.diabres.2021.109063. Online ahead of print.
17. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MA. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes Mellitus 2021;24(3):204-21 (In Russian).
18. Ziegler D, Landgraf R, Lobmann R, Reiners K, Rett K, Schnell O, Strom A. Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in an educational initiative (PROTECT study). Diabetes Research and Clinical Practice 2018 May;139:147-54.
19. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017 Jan;40(1):136-54.
20. Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconja M, Vinik AI, Boulton AJM; Toronto Expert Panel on Diabetic Neuropathy. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes & Metabolism. Research Reviews 2011 Oct;27(7):629-38.
21. Moţăţăianu A, Maier S, Bajko Z, Voidazan S, Bălaşa R, Stoian A. Cardiac autonomic neuropathy in type 1 and type 2 diabetes patients. BMC Neurology 2018 Aug;18(1):126.
22. Calles-Escandón J, Lovato LC, Simons-Morton DG, Kendall DM, Pop-Busui R, Cohen RM, Bonds DE, Fonseca VA, Ismail-Beigi F, Banerji MA, Failor A, Hamilton B. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010 Apr;33(4):721-7.
23. Maffi P, Secchi A. The burden of diabetes: emerging data. Developments in Ophthalmology 2017;60:1-5.
24. Ali Lakhiar M, Naeem Shahbaz N, Hafeez Bughio A, Prakash J. Frequency of peripheral neuropathy in newly diagnosed patients of diabetes mellitus ii on clinical and electrophysiological basis. Pakistan Journal of Neurological Sciences 2014;9(4):31-5.
25. Ziegler D, Papanas N, Zhivov A, Allgeier S, Winter K, Ziegler I, Brüggemann J, Strom A, Peschel S, Köhler B, Stachs O, Guthoff RF, Roden M; German Diabetes Study (GDS) Group. Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes 2014 Jul;63(7):2454-63.
26. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A; KORA Study Group. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008 Mar;31(3):464-9.
27. Papanas N, Vinik AI, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? Nature Reviews. Endocrinology 2011 Jul;7(11):682-90.
28. Asghar O, Petropoulos IN, Alam U, Jones W, Jeziorska M, Marshall A, Ponirakis G, Fadavi H, Boulton AJM, Tavakoli M, Malik RA. Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance. Diabetes Care 2014 Sep;37(9):2643-6.
29. Eleftheriadou A, Williams S, Nevitt S, Brown E, Roylance R, Wilding JPH, Cuthbertson DJ, Alam U. The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review. Diabetologia 2021;64(2):288-303.
30. Chatskaya AV, Korepina OS, Gnezditskiy VV, Tanashyan MM. Autonomic dysfunction in patients with cerebrovascular diseases and metabolic syndrome. Annals of Clinical and Experimental Neurology 2015;9(1):12-9 (In Russian).
31. Apfel SC, Asbury AK, Bril V, Burns TM, Campbell JN, Chalk CH, Dyck PJ, Feldman EL, Fields HL, Gran IA, Griffin JW, Klein CJ, Lindblom U, Litchy WJ, Low PA, Melanson M, Mendell JR, Merren MD, O’Brien PC, Rendell M, Rizza RA, Service FJ, Thomas PK, Walk D, Wang AK, Wessel K, Windebank AJ, Ziegler D, Zochodne DW; Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials. Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. Journal of the Neurological Sciences 2001 Aug;189(1-2):3-5.
32. Ziegler D. [Diabetic polyneuropathy]. Internist 2020 Mar;61(3):243-53.
33. Moon SJ, Rhee EJ, Jung JH, Han KD, Kim SR, Lee WY, Yoon KH. Independent impact of diabetes on the severity of coronavirus disease 2019 in 5,307 patients in South Korea: a nationwide cohort study. Diabetes & Metabolism Journal 2020;44:737-46.
34. Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, Knighton P, Holman N, Khunti K, Sattar N, Wareham NJ, Young B, Valabhji J. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. The Lancet. Diabetes & Endocrinology 2020 Oct;8(10):813-22.
35. Pitocco D, Viti L, Santoliquido A, Tartaglione L, Di Leo M, Bianchi A, Caputo S, Pontecorvi A. Diabetic neuropathy: a risk factor for severe COVID-19? Acta Diabetologica 2021;58(5):669-70.
36. Rogers LC, Snyder RJ, Joseph WS. Diabetes-related amputations a pandemic within a pandemic. Journal of the American Podiatric Medical Association 2020 Nov 3;20-248. doi: 10.7547/20-248. Online ahead of print.
37. Gök Ü, Selek Ö, Selek A, Güdük A, Güner MÇ. Survival evaluation of the patients with diabetic major lower-extremity amputations. Musculoskeletal Surgery 2016 Aug;100(2):145-8.
38. Look AHEAD Research Group. Effects of a long-term lifestyle modification programme on peripheral neuropathy in overweight or obese adults with type 2 diabetes: the Look AHEAD study. Diabetologia 2017 Jun;60(6):980-8.
39. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Current Diabetes Reports 2014;14(9):528.
40. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. The Lancet 1998 Sep;352(9131):837-53.
41. Ismail-Beigi F, Craven T, Banerji MA, Jan Basile J, Jorge Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O’Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I; ACCORD Trial Group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. The Lancet 2010 Aug;376(9739):419-30.
42. Ziegler D, Behler M, Schroers-Teuber M, Roden M. Near-normoglycaemia and development of neuropathy: a 24-year prospective study from diagnosis of type 1 diabetes. BMJ Open 2015 Jun;5(6):e006559.
43. Tavakoli M, Mitu-Pretorian M, Petropoulos IN, Fadavi H, Asghar O, Ponirakis UAG, Jeziorska M, Marshall A, Efron N, Boulton AJ, Augustine T, Malik RA. Corneal confocal microscopy detects early nerve regeneration in diabetic neuropathy after simultaneous pancreas and kidney transplantation. Diabetes 2013 Jan;62(1):254-60.
44. Ishibashi F, Taniguchi M, Kosaka A, Uetake H, Tavakoli M. Improvement in neuropathy outcomes with normalizing HbA1c in patients with type 2 diabetes. Diabetes Care 2019 Jan;42(1):110-8.
45. Cardoso CRL, Leite NC, Moram CBM, Salles GF. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovascular Diabetology 2018 Feb;17(1):33.
46. Jin HY, Lee KA, Park TS. The impact of glycemic variability on diabetic peripheral neuropathy. Endocrine 2016 Sep;53(3):643-8.
47. Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, Waberski BH, Lachin JM, Albers JW; DCCT/EDIC Research Group. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Current Diabetes Reports 2010 Aug;10(4):276-82.
48. Chalmers J, Cooper ME. UKPDS and the legacy effect. The New England Journal of Medicine 2008 Oct;359(15):1618-20.
49. Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson DJ, Perkins B, Russell JW, Zochodne D; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: treatment of painful diabetic neuropathy. Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011 May;76(20):1758-65.
50. Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N, Shigeta Y. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006 Jul;29(7):1538-44.
51. Boulton AJM, Kempler P, Ametov A, Ametov A, Ziegler D. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes/Metabolism. Research and Reviews 2013 Jul;29(5):327-33.
52. International Diabetes Federation. IDF clinical practice recommendations on the diabetic foot – 2017. A guide for healthcare professionals. Brussels, Belgium: IDF; 2017. 70 p.
53. Papanas N, Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opinion on Pharmacotherapy 2014 Dec;15(18):2721-31.
54. El-Nahas MR, Elkannishy G, Abdelhafez H, Elkhamisy ET, El-Sehrawy AA. Oral alpha lipoic acid treatment for symptomatic diabetic peripheral neuropathy: a randomized double-blinded placebo-controlled study. Endocrine, Metabolic & Immune Disorders Drug Targets 2020;20(9):1531-4.
55. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabetic Medicine 2004;21(2):114-21.
56. Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJG. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. International Journal of Endocrinology 2012;2012:456279.
57. Amato Nesbit S, Sharma R, Waldfogel JM, Zhang A, Bennett WL, Yeh HC, Chelladurai Y, Feldman D, Robinson KA, Dy SM. Non-pharmacologic treatments for symptoms of diabetic peripheral neuropathy: a systematic review. Current Medical Research and Opinion 2019 Jan;35(1):15-25.
58. Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Practice 2014 Feb;14(2):167-84.
59. Çakici N, Fakkel TM, van Neck JW, Verhagen AP, Coert JH. Systematic review of treatments for diabetic peripheral neuropathy. Diabetic Medicine 2016 Nov;33(11):1466-76.
60. Ziegler D, Low PA, Litchy WJ, Boulton AJM, Vinik AI, Freeman R, Samigullin R, Tritschler H, Munzel U, Maus J, Schütte K, Dyck PJ. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011 Sep;34(9):2054-60.
61. Agathos E, Tentolouris A, Eleftheriadou I, Katsaouni P, Nemtzas I, Petrou A, Papanikolaou C, Tentolouris N. Effect of α-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy. The Journal of International Medical Research 2018 May;46(5):1779-90.
62. Li G, Fu J, Zhao Y, Ji K, Luan T, Zang B. Alpha-lipoic acid exerts anti-inflammatory effects on lipopolysaccharide-stimulated rat mesangial cells via inhibition of nuclear factor kappa B (NF-κB) signaling pathway. Inflammation 2015 Apr;38(2):510-9.
63. Nádró B, Lőrincz H, Molnár Á, Szentpéteri A, Zöld E, Seres I, Páll D, Paragh G, Kempler P, Harangi M, Sztanek F. Effects of alpha-lipoic acid treatment on serum progranulin levels and inflammatory markers in diabetic neuropathy. The Journal of International Medical Research 2021 May;49(5):3000605211012213.
64. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Population Health Metrics 2010 Oct;8:29.

  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]